. Alteration of intracellular histamine H 2 receptor cycling precedes antagonist-induced upregulation.
THE HISTAMINE H 2 RECEPTOR (H 2 R) belongs to the large family of G protein-coupled receptors (GPCRs) and plays important physiological roles in the regulation of gastric acid secretion, cell differentiation and proliferation, the immunological response, and central nervous system function (4, 9, 11, 25) . H 2 R antagonists have been widely used to treat acid-related diseases such as peptic ulcer and reflux esophagitis. Long-term administration of H 2 R antagonists leads to tachyphylaxis, which is a tolerance to the inhibition of acid secretion, and to rebound acid hypersecretion after any abrupt withdrawal of treatment; both outcomes have important clinical implications (28) . Several clinical studies have confirmed that these phenomena can occur in patients receiving a H 2 R antagonist (22) (23) (24) irrespective of concurrent use of a proton pump inhibitor (6) .
We (37) previously demonstrated that prolonged treatment with the H 2 R antagonist famotidine induced an upregulation of H 2 R and an increase in adenylate cyclase activity in rabbit parietal cells and that this may cause rebound acid hypersecretion. H 2 R acts as a constitutively active GPCR in vitro, and most of the H 2 R antagonists that have been widely used to treat acid-related diseases act as pharmacologically characterized "inverse agonists," which reduce the constitutive activity of the receptor (1, 31) . Upregulation of other GPCRs may be induced by prolonged treatment with antagonists in constitutively active mutants, whereby the antagonist acts as an inverse agonist, but this is not seen with constitutively inactive receptors, for which the antagonists act as a neutral agonist (14, 15, 18, 36) . This antagonist-induced upregulation of H 2 R may be due to positive feedback effects of the inverse agonism of H 2 R antagonists, although a possible mechanism for this has not been demonstrated.
One important physiological mechanism of the regulation of GPCR signaling is receptor endocytosis to endosomes, from where they may be recycled back to the plasma membrane or trafficked to lysosomes for proteolytic degradation (7, 19, 39, 43) . Because different GPCR subtypes show distinct endocytic trafficking patterns (38, 40) , it is crucial to characterize the intracellular trafficking of individual GPCR subtypes. Previous studies into H 2 R regulation have revealed that upon agonist stimulation, H 2 R is desensitized via receptor phosphorylation by G protein receptor kinases (26, 30) , which leads to endocytosis of the receptor (8, 33, 34) . Persistent treatment with an agonist induced H 2 R downregulation in CHO cells expressing rat H 2 R, and this was suggested to be mediated by posttranscriptional mRNA instability (32) . In endothelial cells, persistent treatment with an agonist induced downregulation of both cell surface and mRNA expression of H 2 R (29) . Because most of this evidence is based on binding assays, Western blot analysis of cell lysates, and the second messenger response, little is known about the intracellular trafficking and localization of H 2 R, especially during treatment with a H 2 R antagonist.
The aim of the present study was to investigate the role of receptor trafficking in antagonist-induced upregulation of H 2 R. We therefore sought to characterize the intracellular localization patterns of H 2 R and to examine the effect of a H 2 R antagonist on receptor trafficking in living cells using func-tional green fluorescent protein (GFP)-tagged human H 2 R in HEK-293 cells. We monitored the trafficking of GFP-tagged H 2 R with various markers for intracellular organelles and evaluated changes in the localization of H 2 R upon antagonist exposure. We also examined whether the receptor upregulation is dependent on the augmentation of de novo receptor synthesis.
MATERIALS AND METHODS

Materials.
Histamine dihydrochloride, cycloheximide (CHX), and isobutylmethylxanthine (IBMX) were obtained from Sigma (St. Louis, MO). Famotidine was kindly donated by Yamanouchi (Tokyo, Japan), and cimetidine and ranitidine were kindly donated by GlaxoSmithKline (Tokyo, Japan). [ 3 H]tiotidine was purchased from PerkinElmer Life Science (Boston, MA). A genomic DNA clone of human H2R was kindly provided by Dr. M. Futai (Department of Organic Chemistry and Biochemistry, The Institute of Scientific and Industrial Research, Osaka University, Osaka, Japan).
Construction of GFP-tagged form of human H 2R. The entire coding region of the human H2R gene with the exception of the stop codon was amplified by PCR using an EcoRI forward primer (5Ј-CCG-GAATTCGTCCCAGGATGGCACCC-3Ј) and an ApaI reverse primer (5Ј-GAAGGGCCCACCTGTCTGTGGCTCCCTGG-3Ј) from a gt11 clone template, which contained a 12.3-kb 5Ј-upstream sequence, the 1,080-bp coding region, and a 245-bp 3Ј-downstream sequence (21) . The PCR product (containing nucleotide positions Ϫ8 to 1,077) was digested with EcoRI and ApaI, and the resultant fragment was ligated into the multiple cloning site of the pEGFP-N1 vector (Clontech Laboratories; Palo Alto, CA) to generate an expression vector for a fusion protein of human H 2R and GFP (pH2R-EGFP). The insert for the wild-type human H2R expression vector was constructed as follows: a human H2R clone containing the full coding region and the stop codon was amplified by PCR using an EcoRI forward primer (5Ј-CCGGAATTCGTCCCAGGATGGCA-CCC-3Ј) and a NotI reverse primer (5Ј-AAAGCGGCCGCTTACCT-GTCTGTGGCTCCC-3Ј). The PCR product (containing nucleotide positions Ϫ8 to 1,080) was digested with EcoRI and NotI, and the resultant fragment was ligated into the pEGFP-N1 vector, in which the open reading frame of enhanced GFP (EGFP) had been previously removed (pH 2R-wild).
Cell culture and transfection. HEK-293 cells were maintained in DMEM supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 50 IU/ml penicillin, and 50 g/ml streptomycin at 37°C in 5% CO 2-95% air. The cells were grown to 70 -80% confluence and transiently transfected with 1 g of plasmid DNA per 0.5 ml medium using LipofectAMINE 2000 reagent (Life Technologies; Carlsbad, CA) according to the manufacturer's instructions.
Measurement of cAMP production. HEK-293 cells seeded onto 24-well plates were transfected with pH 2R-EGFP, pH2R-wild, or pEGFP-N1 vector (mock transfection) and incubated for 24 h. The cells were incubated in the presence or absence of various ligands in DMEM-HEPES supplemented with 300 M IBMX, a phosphodiesterase inhibitor, for 10 min at 37°C. After rapid aspiration of the incubation medium, the reaction was stopped by the addition of 200 l of 0.1 M ice-cold HCl. The cells were kept on ice and disrupted by sonication. The resultant homogenate was neutralized with 1 M NaOH and assayed for cAMP content by radioimmunoassay using 125 Ilabeled cAMP with a Yamasa Cyclic AMP Assay Kit (Yamasa Shoyu; Chiba, Japan). cAMP levels were expressed as picomoles of cAMP per milligram of protein per 10 min.
H 2R binding. HEK-293 cells transfected with pH2R-EGFP or pH2R-wild were trypsinized and removed from the plates. A total of 1 ϫ 10 5 cells was transferred to a 0.6-ml centrifuge tube and incubated at 37°C for 80 min with various concentrations of [ 3 H]tiotidine, a radiolabeled H2R antagonist, in sodium phosphate buffer A (132.4 mM NaCl, 5.4 mM KCl, 5.0 mM Na2HPO4, 1.0 mM NaH2PO4, 1.2 mM MgSO4, 1.0 mM CaCl2, 10 mM HEPES, 0.2% bovine serum albumin, and 2 mg/ml glucose; pH 7.4) in a total volume of 200 l. The cell suspension was cooled on ice and centrifuged for 5 min at 15,000 g at 4°C. The supernatant was aspirated, and the resultant pellet was rinsed once with 500 l of ice-cold PBS. The radioactivity was measured with a liquid scintillation counter (LSC-5100, Aloka; Tokyo, Japan). Nonspecific binding was defined as that observed in the presence of 10 M famotidine and estimated by Scatchard plot analysis. Assays were performed in triplicate in time course experiments and in duplicate in the others.
Imaging by confocal and evanescent wave microscopy. Time-lapse images of H 2R-GFP were obtained using a confocal laser microscope (IX 70, Olympus; Tokyo, Japan) equipped with a microlens-attached Nipkow-disk scanner (CSU-10, Yokokawa Electric; Tokyo, Japan), using an Olympus Apo ϫ100 [1.65 numerical aperture (NA)] oilimmersion objective lens. The confocal fluorescence images were recorded with a charge-coupled device camera (C2400, Hamamatsu Photonics; Hamamatsu, Japan) combined with an image intensifier (C2400-21SV, Hamamatsu Photonics) and analyzed with MetaMorph software (Universal Imaging; Downingtown, PA). To avoid losing the object in the single confocal section, three-dimensional confocal images were recorded at 1-m z-intervals, starting at the bottom of the cell using IP Lab (Scanalysis; Fairfax, VA). Cells grown on 35-mm glass-base dishes were used for the experiments in medium without phenol red and antibiotics at 37°C in 5% CO 2-95% air.
To determine the intracellular localization of H2R-GFP and rhodamine-transferrin (Molecular Probes; Eugene, OR), cells were incubated in medium lacking fetal bovine serum for 30 min, followed by an incubation with 40 g/ml rhodamine-transferrin for the indicated time at 37°C in 5% CO2-95% air, and the cells were then quickly rinsed three times to remove all excess rhodamine-transferrin and fixed with 4% paraformaldehyde in PBS (pH 7.4) for 20 min at room temperature before imaging analysis was started. Merged images of H 2R-GFP and rhodamine-transferrin were captured by a Bio-Rad MRC-600 (Hemmelholsteadt, UK) using a Nicon Plan-Apo ϫ60 (1.40 NA) oil-immersion objective. We used the 504-to 524-nm laser line with a 527-to 565-nm band-pass filter and 600-nm long-pass filter for the detection of GFP and rhodamine, respectively.
To assess fluorescence of H 2R-GFP localized in the plasma membrane, we also used evanescent wave microscopy. The incident light for evanescent illumination was introduced from the objective lens [PlanApo ϫ60 (1.45 NA), Olympus]. To observe the GFP fluorescence image, we used a 473-nm laser for the evanescent wave excitation and a long-pass filter (515 nm) for emission. The capture and analysis of the images were performed in the same manner as with the confocal microscope.
Immunocytochemistry. HEK-293 cells grown in 35-mm glass-base dishes were transiently transfected with H 2R-GFP for 24 h. Cells stimulated with 100 M histamine for the indicated times were washed with PBS, fixed with 4% paraformaldehyde in PBS (pH 7.4) for 20 min at room temperature, and then permeabilized with 0.2% Triton X-100 in PBS for 8 min. The cells were then incubated in blocking solution for 5 min before incubation in primary antibody for 1 h at room temperature. Antibodies against early endosomal antigen (EEA)-1 (Transduction Laboratories; San Diego, CA), Rab11 (Zymed Laboratories; San Francisco, CA), Golgin-97 (Molecular Probes), and lysosomal-associated membrane protein (LAMP)-1 (BD BiosciencesPharmigen; San Diego, CA) were diluted 1:100, 1:200, 1:200, and 1:200, respectively. After three washes in PBS, cells were incubated in Alexa 594-conjugated secondary antibody (Molecular Probes) for 1 h. Images were acquired with a Bio-Rad MRC-600 confocal laser scanning microscope using the 504-to 524-nm laser line with a 527-to 565-nm band-pass filter and 600-nm long-pass filter for the detection of GFP and Alexa 594, respectively. Quantification of mRNA levels of H 2R. mRNA expression levels of H2R in HEK-293 cells were quantified and normalized against ␤-actin by real-time quantitative PCR using a Light Cycler rapid thermal cycler system (Roche Diagnostics; Lewes, UK). Isolation of total RNA and cDNA synthesis was performed using a Cells-to-cDNA II kit (Ambion; Austin, TX). The primers used were for H 2R [5Ј-CAATGTGGTCGTCTGTCTGG-3Ј (forward) and 5Ј-AGGCTGTG-CAGAGCATCAC-3Ј (reverse)] and for ␤-actin [5Ј-GCACCACAC-CTTCTACAATGAG-3Ј (forward) and 5Ј-ATAGCACAGCCTG- GATAGCAAC-3Ј (reverse)]. Product specificity was confirmed in the initial experiment by agarose gel electrophoresis and routinely performed by melting curve analysis.
Statistical analysis. Data are expressed as means Ϯ SE. A paired Student's t-test was used for comparisons of increases in H 2R binding sites between control and treated groups. An unpaired Student's t-test was used for comparisons of the H 2R binding characteristics between wild-type H2R and H2R-GFP groups and for comparisons of the H2R binding sites between two groups at each time point in the time course experiment and in the experiment using CHX. A level of P Ͻ 0.05 was considered to be statistically significant.
RESULTS
Functional expression of human H 2 R-GFP fusion protein in
HEK-293 cells. Wild-type human H 2 R and human H 2 R-GFP fusion protein, in which the COOH-terminus of H 2 R was directly linked to the NH 2 -terminus of EGFP, were transiently transfected into HEK-293 cells (Fig. 1A) 1 ). Both overexpressed H 2 R-GFP and wild-type H 2 R in HEK-293 cells showed the same degree of agonist-independent constitutive activity for adenylate cyclase, which was measured as any elevation of basal cAMP levels. The specific H 2 R antagonists famotidine and cimetidine decreased the basal production of cAMP, indicating that both acted as inverse agonists. Histamine (100 M) markedly increased the levels of cAMP in both H 2 R-GFP-and wild-type H 2 R-transfected cells (Table 1) .
We then examined whether persistent treatment with various H 2 R antagonists for 24 h could induce upregulation of H 2 R-GFP or wild-type H 2 R in HEK-293 cells. No effect on the affinity for [ 3 H]tiotidine was recorded in either of the transfected cells (data not shown). B max increased by approximately twofold irrespective of the presence of GFP (Table 1 ). These results showed that both H 2 R-GFP and wild-type H 2 R were functionally coupled to intracellular signaling and could be regulated by ligand treatment.
In resting HEK-293 cells, H 2 R-GFP was predominantly observed at the plasma membrane by confocal microscopy (Fig. 1B) . Evanescent wave microscope (41) also showed that H 2 R-GFP diffusely but prominently localized to the plasma membrane of resting cells in culture dishes (Fig. 1C) . 
Agonist-induced internalization of H 2 R-GFP in HEK-293 cells.
To determine the intracellular localization of H 2 R in detail, we first examined the intracellular trafficking of H 2 R-GFP during agonist exposure. To assess the change in intracellular localization of H 2 R-GFP, the three-dimensional distribution of internalized H 2 R-GFP was determined using confocal time-lapse imaging in sequential z-axis planes. Imaging in living cells expressing H 2 R-GFP after treatment with 100 M histamine revealed internalized GFP in discrete intracellular vesicles at 30 min and thereafter in the perinuclear region up to 120 min (Fig. 2A) . We also examined whether antagonist treatment causes any internalization of H 2 R-GFP. There was no internalization of H 2 R-GFP during treatment, up to 120 min, with 100 M famotidine or 100 M cimetidine (Fig. 2, B  and C) .
To confirm that the agonist-induced internalization of H 2 R-GFP corresponded to receptor endocytosis, we examined the colocalization of H 2 R-GFP with rhodamine-transferrin, a fluorescent marker of endocytosis. Internalized H 2 R-GFP showed overlapping staining with transferrin in endosomal compartments at both 30 and 60 min after histamine treatment (Fig. 3) .
Characterization of H 2 R-GFP-positive intracellular compartments.
To determine the specific intracellular organelle involved in H 2 R internalization, cells were stained with markers for early endosomes (EEA-1) (3, 20) , perinuclear recycling endosomes (Rab11) (35, 42, 45) , the trans-Golgi network (Golgin-97), and lysosomes (LysoTracker red) and then observed for the localization of H 2 R-GFP. After 30 min in the presence of 100 M histamine, H 2 R-GFP translocated to the early endosome, stained with EEA-1 (Fig. 4E) , and by 60 min was localized in the perinuclear recycling endosome, identified by Rab11 (Fig. 4F ). There was little or no colocalization of H 2 R-GFP with Golgin-97 (Fig. 4G) or LysoTracker red (Fig.  4H ) during internalization.
Short exposure to antagonist (inverse agonist) induces recycling of internalized H 2 R-GFP.
To examine whether antagonist induces trafficking of the internalized H 2 R, we performed time-lapse imaging of living cells expressing H 2 R-GFP in sequential z-axis planes. In the presence of 100 M famotidine, histamine (100 M) could not induce the internalization of H 2 R-GFP (Fig. 5A) . The further addition of 100 M famotidine after pretreatment with 100 M histamine recycled the internalized H 2 R-GFP to the plasma membrane within 120 min (Fig. 5B) . When the antagonist (famotidine) was not added, histamine-induced internalization of H 2 R-GFP continued in the same duration (Fig. 5C) .
Long exposure to antagonist (inverse agonist) induces upregulation of H 2 R-GFP.
To visualize the antagonist-induced upregulation of H 2 R-GFP, we used both confocal and evanescent wave microscopy to follow changes in GFP fluorescence in H 2 R-GFP-transfected living cells upon continuous treatment with 10 M famotidine or 100 M cimetidine for 24 h. When HEK-293 cells expressing H 2 R-GFP were treated with these H 2 R antagonists, there was a marked increase in GFP fluorescence in the plasma membrane compared with control levels (Fig. 6A) . By evanescent wave microscopy, this increase in fluorescence was clearly detected adjacent to the basal plasma membrane attached to the glass-base dish. In the presence of 100 M cimetidine, the diffuse fluorescence in the plasma membrane increased in a time-dependent manner (Fig. 6B) .
Time course of H 2 R-GFP upregulation estimated by binding assay.
To characterize the time course of antagonist-induced upregulation, we also quantified H 2 R-GFP using the [ 3 H]tiotidine binding assay. Upon continuous treatment with 100 M cimetidine, [ 3 H]tiotidine binding sites in HEK-293 cells expressing H 2 R-GFP significantly increased at 3 h, followed by a slower but persistent increase up to 24 h (Fig. 7A) . To determine whether the antagonist-induced upregulation was reversible, HEK-293 cells expressing H 2 R-GFP continuously treated with 100 M cimetidine for 24 h were rinsed to remove cimetidine. [ 3 H]tiotidine binding, which was twofold higher with cimetidine treatment than in the control, gradually decreased to almost the control levels by 48 h after the removal of cimetidine (Fig. 7B) .
Analysis of mRNA levels and protein synthesis for upregulation of H 2 R-GFP. To determine whether upregulation of H 2 R-GFP is mediated by an increase in mRNA levels, we performed real-time RT-PCR to quantify H 2 R mRNA over time. Treatment with famotidine or cimetidine had no detectable effects on the levels of H 2 R-GFP mRNA (Fig. 8A) . To determine whether the upregulation is mediated at the translational level, we treated cells with CHX, an inhibitor of translation. Upregulation of H 2 R-GFP induced by 100 M cimetidine for 24 h was dose dependently inhibited in the concurrent presence of CHX, although CHX did not alter the receptor amount without cimetidine (Fig. 8B) . Thus antagonist-induced upregulation of H 2 R depends on the translation of H 2 R, whereas the receptor amount without ligand treatment (control experiment) is independent of protein translation. Furthermore, we asked whether maintenance of H 2 R upregulation depended on augmentation of H 2 R translation. Once the receptor was upregulated by the pretreatment with 100 M cimetidine, the receptor amount was not affected by the addition of 60 g/ml CHX in the presence of 100 M cimetidine. In addition, after upregulation, the receptor number still decreased after the removal of cimetidine irrespective of the presence of CHX (Fig. 8C) , indicating that CHX did not inhibit protein degradation. These findings suggested that the initial upregulation requires de novo protein synthesis, but this is not needed to maintain subsequent increases in receptor level.
Degradative trafficking of H 2 R-GFP expressed in HEK-293 cells.
Because the antagonist-induced upregulation of H 2 R is suggested to depend on suppressing H 2 R degradation, we tried to confirm the degradative pathway of H 2 R-GFP expressed in HEK-293 cells. In many GPCRs, degradative trafficking has been observed before downregulation of the receptor with long exposure to agonist. Thus we examined whether H 2 R-GFP translocated to the lysosomal pathway with long exposure to H 2 R agonist. LAMP-1 is located in the limiting membranes of lysosomal pathway involving lysosomes and late endosomes (5) . The application of 100 M histamine for 6 h increased the colocalization between intracellular H 2 R-GFP and LAMP-1 (Fig. 9) . This finding indicated that with agonist exposure the postendocytic pathway of H 2 R-GFP in HEK-293 cells was associated with the lysosomal pathway, resulting in receptor degradation. dose-dependent inhibition by cycloheximide (CHX) of cimetidine-induced upregulation at 24 h. In each CHX treatment group, the assay was performed with or without 100 M cimetidine. Data represent means Ϯ SE in triplicate assays. Similar results were obtained in 3 independent experiments. *P Ͻ 0.05 compared with the values without cimetidine (control). C: treatment with CHX had no effect on either the upregulation of H2R-GFP or the recovery to normal levels after the removal of the antagonist. The receptor number upregulated by pretreatment with 100 M cimetidine was not affected by the addition of 60 g/ml CHX for 24 h, and recovery from upregulation after the removal of the antagonist was observed even in the presence of 60 g/ml CHX. Data shown as a percentage of the levels in control cells represent means Ϯ SE in triplicate assays. Similar results were obtained in 3 independent experiments. NS, not significant. *P Ͻ 0.05 compared with the values with cimetidine in each CHX treatment group.
DISCUSSION
This study is the first to use living cells expressing functional GFP-tagged H 2 R to visualize intracellular H 2 R localization and sorting. The addition of GFP to the COOH-terminus of GPCRs has proven effective in monitoring the cellular distribution and regulation of these receptors (12) . This study examined the mechanisms underlying the upregulation and intracellular trafficking of human H 2 R-GFP during treatment with an antagonist (inverse agonist). The main findings were that 1) agonistdependent internalization involved initial accumulation in early endosomes, followed by trafficking to recycling endosomes; 2) short exposure to an antagonist (inverse agonist) induced recycling of the agonist-induced internalized receptor within 2 h; 3) long exposure to an antagonist (inverse agonist) for at least 3 h induced reversible upregulation of H 2 R, probably by suppressing H 2 R degradation; and 4) long exposure to an agonist enhanced the degradative trafficking of H 2 R-GFP. Initially, we demonstrated that H 2 R was trafficked to the recycling endosome via early endosomes upon short exposure to agonist and then back to the plasma membrane upon agonist withdrawal. The trafficking pathway is similar to that used by transferrin and transferrin receptor, which have been well characterized. The time course of trafficking seems to vary among GPCRs. In the present study, H 2 R was internalized more slowly than the ␤ 2 -adrenoceptor (13, 17, 44) , angiotensin II type 1A receptor (10) , or the serotonin type 2A receptor (2) . This finding was consistent with the available data demonstrated in cell lines expressing H 2 R without a GFP tag, although the reasons for this difference in trafficking time among these receptors remains unclear.
Previous studies showed that longer exposure to a H 2 R antagonist induced upregulation of H 2 R (31, 37). In this study, we found this upregulation of H 2 R to be reversible upon withdrawal of the antagonist. In addition, we imaged the upregulation of H 2 R in the plasma membrane of living cells by confocal and evanescent wave microscopies, although the time-lapse imaging provides data that are only semiquantitative. Antagonist-induced upregulation of H 2 R was not due to any increase in the mRNA level but was initially inhibited by CHX, suggesting that de novo receptor protein synthesis was required for this initial step. These results are consistent with those in a previous report that demonstrated that upregulation of a ␤ 2 -adrenoceptor constitutively active mutant induced by sustained treatment with an antagonist (inverse agonist) was not regulated at the mRNA level but was sensitive to inhibition of protein synthesis (14, 15) . Of note, the elevated levels of H 2 R were not affected by the addition of CHX after cimetidine pretreatment, suggesting that the contribution of protein synthesis to maintaining elevated receptor levels is not considerable. These results indicate that translation is kept on a certain level and that receptor degradation and synthesis are in balance, irrespective of CHX treatment, and thus the equilibrium maintains the upregulation.
In the present study, we demonstrated two effects of antagonist (inverse agonist) on H 2 R regulation: 1) recycling to the In the resting state, ligand-independent endocytosis is in balance with receptor recycling back to the plasma membrane, as is de novo receptor synthesis and degradation via the endosome-lysosome pathway. In this state, the total number of receptors remains constant. A: short exposure to antagonist (inverse agonist) shifts the equilibrium between endocytosis and recycling predominantly to recycling. Consequently, the number of receptors localized in endosomes decreases. B: upon long exposure to antagonist (inverse agonist), the decrease in endosomal receptor pool may lead to a subsequent reduction in receptor degradation via trafficking to lysosomes. Therefore, de novo receptor synthesis predominates over degradation. In this state, the total number of receptors increases up to the altered point of equilibrium. EE, early endosome; RE, recycling endosome; LE, late endosome; N, nucleus; Lyso, lysosome. plasma membrane without any detectable change in total receptor amount within 2 h and 2) upregulation after long exposure to antagonist. The direct link between antagonistinduced upregulation and recycling of H 2 R remains unclear, and no previous studies have discussed this link. However, in the case of downregulation induced by a persistent exposure to an agonist, receptor proteolysis via preceding endocytosis plays a major role (16, 39) . Many GPCRs are regulated by endocytosis, in that short exposure to an agonist induces an increase in the perinuclear endosomal receptor pool due to receptor endocytosis before downregulation, probably by trafficking to lysosomes for degradation. In our expression system, we confirmed that this degradative pathway of H 2 R-GFP certainly exists during long exposure to 100 M histamine because of colocalization with LAMP-1. In this study, antagonistinduced upregulation was observed at 3 h after treatment, whereas the decrease in the endosomal receptor was complete within 2 h. The decreased receptor pool in endosomes may lead to a subsequent reduction in receptor degradation. A part of the H 2 R upregulation upon long exposure to an antagonist needs de novo protein synthesis. The longer period for induction of H 2 R upregulation compared with other GPCRs probably corresponds to the time needed for redistribution of newly synthesized receptors. The upregulation could then be maintained by suppression of receptor degradation rather than augmentation of receptor synthesis. Taking these previous results and our current observations together, we propose a model for antagonist-induced upregulation of H 2 R (Fig. 10 ). In this model, the recycling endosome acts as an intracellular pool of membrane proteins rather than a mere point of recycling passage, which is supported by models proposed for other membrane receptors, channels, and transporters (27) . Inverse agonist-induced redistribution of the H 2 R to the plasma membrane may reduce the normal degradation of the H 2 R, thereby shifting the synthesis-degradation balance and resulting in a net increase in H 2 R.
In conclusion, visualization of H 2 R in living cells revealed that a H 2 R antagonist, which acts as an inverse agonist, induced recycling of the agonist-induced internalized receptor from the endosomal pool to plasma membrane within 2 h. Persistent treatment with an antagonist induced upregulation of H 2 R-GFP after at least 3 h, especially in the plasma membrane. Upregulation of H 2 R-GFP is reversible after withdrawal of the antagonist. Treatment with an antagonist did not augment H 2 R mRNA, and subsequent inhibition of protein synthesis by CHX had no effect on H 2 R upregulation. The shift in equilibrium of receptor trafficking between endocytosis and recycling, which precedes H 2 R upregulation, occurs concurrently with suppression of receptor degradation and may explain the inverse agonist-induced upregulation of H 2 R.
